Annexon develops targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases, with programs built around C1q and the classical complement pathway. Company news centers on clinical and regulatory progress for vonaprument in geographic atrophy, tanruprubart in Guillain-Barré syndrome, and ANX1502 as an oral C1 inhibitor for autoimmune disease.
Recurring updates also include quarterly financial results, research and development spending, cash runway disclosures, investor conference presentations, key opinion leader events, and equity inducement grants under Nasdaq rules. The company’s announcements connect pipeline progress with its balance sheet and public-company governance activity.
Annexon (Nasdaq: ANNX) appointed renowned retinal surgeon and biotechnology entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its board of directors, adding more than four decades of clinical, scientific and corporate leadership in retinal disease. Annexon also reported that long-serving director and investor Muneer Satter will step down from the board after more than 11 years of service.
According to Annexon, Dr. Blumenkranz’s expertise in retinal surgery, drug delivery, imaging and gene therapy, and his history of founding and leading multiple ophthalmic and life science companies, is expected to support the company as it advances vonaprument for geographic atrophy toward pivotal Phase 3 data and potential registration, and progresses its C1q‑targeted platform for neuroinflammatory diseases.
Annexon (Nasdaq: ANNX) reported early data from the first 10 U.S. and European patients with Guillain-Barré syndrome (GBS) in its ongoing open-label FORWARD study of tanruprubart. All patients showed rapid, clinically meaningful improvement in muscle strength within four days after a single 30 mg/kg infusion.
Four previously bedbound patients walked with or without assistance between days two and eight, and one ventilated patient was off ventilation within four days. Five other patients had marked functional gains within 48 hours. Tanruprubart was generally well-tolerated, with adverse events mainly related to GBS, and results were described as consistent with a prior Phase 3 study in which about 90% of patients improved by day 8. According to Annexon, FORWARD data are expected to support a planned BLA submission in Q4 2026, while a Marketing Authorisation Application is already under review by the EMA.
Annexon (Nasdaq: ANNX) entered a strategic credit facility with Oxford Finance for up to $200 million, expanding its financial capacity as vonaprument and tanruprubart advance toward registration. The facility is characterized by the company as non-dilutive capital to support potential global commercialization and long-term growth.
According to Annexon, it drew an initial $50 million at closing. An additional $100 million may become available upon achieving specified milestones in the vonaprument and tanruprubart registrational programs, with the remaining $50 million accessible subject to lender approval.
Annexon (Nasdaq: ANNX) granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options for an aggregate 335,000 common shares.
The options have a ten-year term and an exercise price of $6.50 per share, equal to the July 15, 2026 closing price. Vesting occurs over four years: 25% after one year, then 1/48 of the shares monthly, subject to continued service.
Annexon (Nasdaq: ANNX) announced an oral presentation at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, held July 15–18, 2026, in Montréal, Canada, highlighting Phase 2 ARCHER data for vonaprument in dry age-related macular degeneration (AMD) with geographic atrophy (GA).
The presentation will focus on baseline characteristics linked to best corrected visual acuity (BCVA) ≥15-letter loss, based on the Phase 2 ARCHER trial in which vonaprument demonstrated significant vision preservation in GA patients. These findings are intended to inform patient selection for the ongoing Phase 3 ARCHER II trial, for which topline pivotal data are expected in the fourth quarter of 2026. Vonaprument is described as a first-in-kind, non-pegylated antigen-binding fragment (Fab) targeting C1q, an aberrant trigger of neurodegeneration in GA. The oral presentation, titled “Baseline Characteristics Associated with Loss of BCVA ≥15 ETDRS Letters in Participants with Geographic Atrophy in the Phase 2 ARCHER Study,” will be delivered by Margaret Chang, M.D., M.S., of Retinal Consultants Medical Group, on Saturday, July 18, 2026, at 10:44 am Eastern Daylight Time (EDT).
Annexon (Nasdaq: ANNX) granted stock options as inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
The employees received options to buy 705,000 shares at $4.64 per share, with a ten-year term and four-year vesting schedule.
Annexon (Nasdaq: ANNX) announced that president and CEO Douglas Love will join fireside chats at two June 2026 investor conferences.
He will appear at the Jefferies Global Healthcare Conference on June 3, 2026 at 11:40 a.m. ET in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 at 8:00 a.m. ET in Miami Beach. Live webcasts and 30-day replays will be available in the Events & Presentations section of Annexon’s investor website.
Annexon (Nasdaq: ANNX) granted equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4). The awards cover options for 243,000 shares at a $5.21 exercise price, with a ten-year term and four-year vesting schedule.
Annexon (Nasdaq: ANNX) reported Q1 2026 results and portfolio progress, with key near-term clinical and regulatory milestones. Topline Phase 3 ARCHER II data for vonaprument in geographic atrophy is expected in Q4 2026. Tanruprubart MAA is under EMA review and a BLA submission with FORWARD data is anticipated in 2026. ANX1502 proof-of-concept data is expected in 2026. Cash, cash equivalents and short-term investments totaled $225.0 million as of March 31, 2026, with runway into the second half of 2027.
Annexon (Nasdaq: ANNX) will present at the Bank of America Securities Health Care Conference on May 13, 2026 at 11:20 a.m. PT. Douglas Love, President and CEO, will deliver the presentation.
A live webcast is available via the company Investors page and a replay will be archived for 30 days.